Role of Salmonella enterica exposure in Chilean Crohn's disease patients

Table 1 Characteristics of Crohn’s disease patients n (%)

Characteristic	n = 94
Gender
Female	54 (57)
Age at diagnosis (yr)
Median (range)	31 (9-80)
Early onset (< 40 yr)	61 (64.0)
Follow-up (yr)
Median (range)	7.0 (2.0-34.0)
Smoking at diagnosis	31 (32.0)
History of gastroenteritis due to SE	5 (5.0)
Previous appendectomy	20 (21.0)
Disease localization
Ileum	30 (31.9)
Ileocolonic	29 (30.8)
Colon	32 (31.9)
Upper gastrointestinal tract	3 ( 3.1)
Disease behavior
Non-stricturing, non-penetrating	59 (62.7)
Stricturing	24 (25.5)
Penetrating	15 (15.9)
Perianal disease	23 (24.4)
Extraintestinal manifestation	49 (52.1)
Family history of IBD	14 (14.8)

SE: Salmonella enterica; IBD: Inflammatory bowel disease.

Table 2 Comparison between Crohn’s disease patients exposed and those not exposed to Salmonella enterica

	IgG SE (+) (n = 16)	IgG SE (-) (n = 78)
Age at diagnosis (yr)	38.6 ± 15.6	34.9 ± 15.1
Female	6 (37.5)	48 (61.5)
Disease duration, years (yr)	11.2 ± 9.5	8.5 ± 6.1
Disease site
Ileum	5 (31.2)	25 (32.0)
Ileocolonic	6 (37.5)	23 (29.4)
Colonic	5 (31.2)	27 (34.6)
Proximal	0 (0.0)	3 (3.8)
Perianal disease	1 (6.2)	22 (28.2)
Disease Behaviour
Inflammatory	12 (75)	47 (60.2)
Stricturing	2 (12.5)	22 (28.2)
Penetrating	2 (12.5)	13 (16.6)
Family history of IBD	3 (18.7)	11 (14.1)
Active smokers	10 (62.5)	21 (26.9)b
Previous appendectomy	6 (37.5)	14 (17.9)
Oral contraceptive use	1 ( 6.2 )	4 (5.1)
Extraintestinal involvement	7 (43.7)	42 (53.8)
Immunosuppressants use	11 (68.7)	55 (70.5)
Steroid use	13 (81.2)	67 (85.8)
Anti TNF therapy	1 (6.2)	7 (8.9)
Hospitalization due to IBD	13 (81.2)	58 (74.3)
Bowel Surgery	3 (18.7)	26 (33.3)
NOD2/CARD15 Variant	5 (31.2)	12 (15.3)

Data are expressed as absolute numbers (percentage) or mean ± SD.

^bP < 0.01 vs IgG Salmonella enterica (SE) (+). IBD: Inflammatory bowel disease; TNF: Tumor necrosis factor.